Skip to main content

Published works by Gregg Weiner

LEX-AR-MMJPK6RZ · complete body of work · page 1 of 1 · 20 works

Published works

When Cyberwar Hits the Corporate Home Front
RopesDataPhiles · March 17, 2026
LEX-WK-YZX8NEE2
Annual Securities Class Action Report Shows Life Sciences Firms Remain a Top Target for Claims
Life Sciences Securities Litigation · February 18, 2022
LEX-WK-FSY6FXTR
Year-End NERA Report Shows COVID-19-Related Federal Securities Litigation Disproportionately Targeting Life Sciences Firms
Life Sciences Securities Litigation · February 1, 2021
LEX-WK-1DC8CX16
S.D.N.Y. Rejects Proposed Amended Complaint Alleging Manufacturer Of Liver Disease Drug Intended To Commit Fraud By Not Disclosing Serious Adverse Events
Life Sciences Securities Litigation · September 21, 2020
LEX-WK-707YZ43X
Mid-Year NERA Report Shows COVID-19-Related Federal Securities Litigation Targeting Pharmaceutical Industry
Life Sciences Securities Litigation · July 17, 2020
LEX-WK-8AKVK8CD
S.D.N.Y. Preliminarily Approves $1.6 Million Settlement in Class Action Concerning Development of an OxyContin Alternative
Life Sciences Securities Litigation · July 17, 2020
LEX-WK-NX2G6R7Y
S.D.N.Y. Partially Dismisses Claims Against Pharmaceutical Company, But Allows Claim Regarding Misleading Statements About Upcoming NDA for Rare Tissue Disorder To Proceed
Life Sciences Securities Litigation · June 16, 2020
LEX-WK-RZ3285DV
District of New Jersey Dismisses Action Regarding Company’s Statements Concerning Drug Delivery System’s Safety
Life Sciences Securities Litigation · April 28, 2020
LEX-WK-0548DPS5
First Circuit Affirms Dismissal of Action Regarding Statements Concerning Manufacturing of Eye Drug
Life Sciences Securities Litigation · April 9, 2020
LEX-WK-717XE9A0
S.D.N.Y. Dismisses Action due to Plaintiffs’ Failure to Link Occurrences of Serious Adverse Events to Liver Disease Drug
Life Sciences Securities Litigation · March 26, 2020
LEX-WK-V62DS6ZJ
Cornerstone Research Report Shows Continued Rate of Federal Securities Litigation Filings Targeting Pharmaceutical Industry
Life Sciences Securities Litigation · January 29, 2020
LEX-WK-J5RKTN2F
District Court Judge Partially Dismisses Claims Against Celgene, But Allows Allegations Regarding Misleading Statements About Sales Projections and FDA Approval to Proceed
Life Sciences Securities Litigation · December 19, 2019
LEX-WK-Y8JJWB1T
District of New Jersey Dismisses Action For Failure to Allege Materiality of Non-Disclosure of a Conflict of Interest
Life Sciences Securities Litigation · June 17, 2019
LEX-WK-AG8HHVES
District Judge Finds Error in Previous Dismissal of Action Against Acquirer of Blood Testing Manufacturer
Life Sciences Securities Litigation · May 20, 2019
LEX-WK-61M5AAQ2
D. Mass Holds Plaintiffs Failed to Plead Securities Law Violation Regarding Company’s Statements Concerning Manufacturing of Eye Drug
Life Sciences Securities Litigation · May 1, 2019
LEX-WK-P8MRHJ2G
S.D.N.Y. Dismisses Investor Suit Concerning Pancreatic Cancer Drug Study
Life Sciences Securities Litigation · February 13, 2019
LEX-WK-RMQPYF2A
NERA Report Shows Continued Focus of Plaintiffs’ Securities Bar on the Pharmaceutical Industry
Life Sciences Securities Litigation · February 1, 2019
LEX-WK-AF2Y5G25
District Judge Dismisses Securities Class Action Against Novan, Inc. Relating To Disclosure of FDA Recommendations About Clinical Trials
Life Sciences Securities Litigation · January 29, 2019
LEX-WK-BDTPXQPP
S.D.N.Y. Partially Dismisses Shareholder Class Action Claims Based on Pharmaceutical Company’s Nonactionable Statements of Opinion
Life Sciences Securities Litigation · December 18, 2018
LEX-WK-QBZHN8J4
Unanimous Sixth Circuit Reverses Dismissal, Finding Plaintiffs Plausibly Alleged Defendants Knew Statements Summarizing FDA Meeting Were False
Life Sciences Securities Litigation · September 27, 2018
LEX-WK-MQ90ET2B